484 related articles for article (PubMed ID: 12005089)
21. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
22. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
[TBL] [Abstract][Full Text] [Related]
23. Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience.
Cesaro S; Strugo L; Alaggio R; Cecchetto G; Rigobello L; Pillon M; Cusinato R; Zanesco L
Support Care Cancer; 2003 Nov; 11(11):722-7. PubMed ID: 13680324
[TBL] [Abstract][Full Text] [Related]
24. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
25. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.
Vehreschild JJ; Böhme A; Reichert D; Kiehl MG; Arenz D; Pankraz K; Kochanek M; Ullmann AJ; Cornely OA
Int J Hematol; 2008 Mar; 87(2):126-131. PubMed ID: 18288564
[TBL] [Abstract][Full Text] [Related]
26. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
Mouas H; Lutsar I; Dupont B; Fain O; Herbrecht R; Lescure FX; Lortholary O;
Clin Infect Dis; 2005 Apr; 40(8):1141-7. PubMed ID: 15791514
[TBL] [Abstract][Full Text] [Related]
27. Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
[TBL] [Abstract][Full Text] [Related]
28. The use of voriconazole for the treatment of aspergillosis in falcons (Falco species).
Di Somma A; Bailey T; Silvanose C; Garcia-Martinez C
J Avian Med Surg; 2007 Dec; 21(4):307-16. PubMed ID: 18351011
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis.
Jain LR; Denning DW
J Infect; 2006 May; 52(5):e133-7. PubMed ID: 16427702
[TBL] [Abstract][Full Text] [Related]
30. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
31. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole.
Jacobs F; Selleslag D; Aoun M; Sonet A; Gadisseur A
Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):1173-9. PubMed ID: 21971820
[TBL] [Abstract][Full Text] [Related]
32. Voriconazole: review of a broad spectrum triazole antifungal agent.
Kofla G; Ruhnke M
Expert Opin Pharmacother; 2005 Jun; 6(7):1215-29. PubMed ID: 15957974
[TBL] [Abstract][Full Text] [Related]
33. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease.
van 't Hek LG; Verweij PE; Weemaes CM; van Dalen R; Yntema JB; Meis JF
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1694-6. PubMed ID: 9603157
[TBL] [Abstract][Full Text] [Related]
35. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
36. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
Cordonnier C; Rovira M; Maertens J; Olavarria E; Faucher C; Bilger K; Pigneux A; Cornely OA; Ullmann AJ; Bofarull RM; de la Cámara R; Weisser M; Liakopoulou E; Abecasis M; Heussel CP; Pineau M; Ljungman P; Einsele H; ;
Haematologica; 2010 Oct; 95(10):1762-8. PubMed ID: 20634495
[TBL] [Abstract][Full Text] [Related]
37. Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice.
Heinz WJ; Silling G; Böhme A
Curr Med Res Opin; 2011 Feb; 27(2):335-42. PubMed ID: 21155707
[TBL] [Abstract][Full Text] [Related]
38. [Voriconazole - applications and perspectives].
Ruhnke M
Mycoses; 2002; 45 Suppl 3():42-7. PubMed ID: 12690971
[TBL] [Abstract][Full Text] [Related]
39. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.
Chishimba L; Niven RM; Cooley J; Denning DW
J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765
[TBL] [Abstract][Full Text] [Related]
40. Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis.
Zhang XZ; Huang XE; Xu YL; Zhang XQ; Su AL; Shen ZS
Asian Pac J Cancer Prev; 2012; 13(5):2415-8. PubMed ID: 22901231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
